New experimental drug BMS-986500 enters first human trials for advanced cancers

NCT ID NCT06997029

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulvestrant) for breast cancer patients. The main goals are to check safety, find the right dose, and see how the body processes the drug. About 234 participants are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986500 (an experimental drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors and breast cancer that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. The drug may not work or could have serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma neoplasm ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER ADVANCED OVARIAN CANCER ADVANCED SOLID TUMOR

Contacts and locations

Locations

Copenhagen University Hospital
RECRUITING

Copenhagen, 2100, Denmark
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Dartmouth-Hitchcock Medical Center
RECRUITING

Lebanon, New Hampshire, 03756, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States
Kansai Medical University Hospital
RECRUITING

Hirakata, Osaka, 573-1191, Japan
Local Institution - 0008
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
Local Institution - 0011
NOT_YET_RECRUITING

New York, New York, 10016, United States
Marin Cancer Care
RECRUITING

Greenbrae, California, 94904, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Northwell Health-Cancer Institute
RECRUITING

New Hyde Park, New York, 11042, United States
Odense Universitetshospital
RECRUITING

Odense, Region Syddanmark, 5000, Denmark
Providence St. Jude Medical Center
RECRUITING

Fullerton, California, 92835, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
START Dallas Fort Worth
RECRUITING

Fort Worth, Texas, 76104, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294-3300, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.